Acta Scientific Pharmacology

Short Communication Volume 2 Issue 1

Conflicts Between Evidence and Clinical Practice-current Scenario in Paediatric Neuro Rehabilitation

Janani Ravi1* and Arunachalam Ramachandran2

1Assistant Professor, Faculty of Physiotherapy, Meenakshi Academy of Higher Education and Research, Chennai, India
2Principal and Professor, College of Physiotherapy, Madav University, Rajasthan, India

*Corresponding Author: Janani Ravi, Assistant Professor, Faculty of Physiotherapy, Meenakshi Academy of Higher Education and Research, Chennai, India.

Received: June 05, 2020; Published: December 30, 2020



  The 2019-novel coronavirus (CoV) is a major source of disaster in the 21st century. However, the lack of specific drugs to prevent an attack is a major need at this current point of time. COVID-19 is a disease occurred due to corona virus. In this regard, I have conducted a systematic review to identify possible treatment of corona virus (CoV). The search based on it including herbal and allopathic drugs as no any vaccines and medicines are available to treat COVID-19. Till 22nd September 2020, the numbers of patients currently infected are 31,174,627 from which 962,613 people were died. Thus, this review provides beneficial treatment in current situation. Starting from 2005 to 2020 some major studies have been done to treat this corona virus including traditional Chinese medicines. First time this disease was observed in chine in 2002, so after 2003 the research was started on corona virus, currently known as COVID-19.

Keywords: Corona Virus; COVD-19; Allopathic Drugs; Herbal Medicines



  1. Liu W., et al. “Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV”. Chembiochem5 (2020): 7030-738.
  2. MW R., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) In vitro”. Cell Research (2020).
  3. Kit-Man L., et al. “Immunomodulatory and anti-SARS activities of Houttuynia cordata”. Journal of Ethnopharmacology 118 (2008): 79-85.
  4. Shi-you L., et al. “Identification of natural compounds with antiviral activities against SARS-associated coronavirus”. Antiviral Research 67 (2005): 18-23.
  5. Cheng-Wen L., et al. “Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds”. Antiviral Research 68 (2005): 36-42.
  6. Cheng-Wei Y., et al. “Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus”. Antiviral Research 88 (2010): 160-168.
  7. Young Bae R., et al. “Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition”. Bioorganic and Medicinal Chemistry 18 (2010): 7940-7947.
  8. Mi-Sun Y., et al. “Identification of myricetin and Scrutellare as novel chemical inhibitors of the SARS coronavirus helicase nsP13”. Bioorganic and Medicinal Chemistry Letters 22 (2012): 4049-4054.
  9. Deng-hai Z., et al. “In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus”. Journal of Integrative Medicine 18 (2020): 152-158.
  10. Sophie Alexandra B., et al. “Teicoplanin: an alternative drug for the treatment of COVID-19”. International Journal of Antimicrobial Agents 18 (2020): 105944.
  11. Didier R., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”. International Journal of Antimicrobial Agents1 (2020): 105949.
  12. Lisi D., et al. “Arbidol combined with LPV/r verses LPV/r alone against corona virus disease 2019: A Retrospective cohort study”. Journal of Infection1 (2020): e1-e5.




Citation: Janani Ravi., et al. “Conflicts Between Evidence and Clinical Practice-current Scenario in Paediatric Neuro Rehabilitation.".Acta Scientific Pharmacology 2.1 (2020): 18-19.


Acceptance rate36%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US